Modelling the impact of respiratory syncytial virus (RSV) vaccine and immunoprophylaxis strategies in New Zealand

Please note a website outage is scheduled for Thursday 11 July from 6-8am. We apologise for any inconvenience.

Respiratory illness dashboard STI Quarterly dashboard Wastewater dashboard Measles dashboard Meningococcal disease dashboard Notifiable disease dashboard Pertussis dashboard IPD dashboard

What can we help you find today?

Suggested keywords

Expertise

Digital library

People

Modelling the impact of respiratory syncytial virus (RSV) vaccine and immunoprophylaxis strategies in New Zealand

Abstract

Our results suggest that either a maternal RSV vaccine or mAb would effectively reduce RSV hospitalization disease burden in New Zealand. Overall, a seasonal mAb resulted in a larger disease prevention impact than a maternal vaccine.

view journal

What can we help you find today?

Suggested keywords

Expertise

Digital library

People

Modelling the impact of respiratory syncytial virus (RSV) vaccine and immunoprophylaxis strategies in New Zealand

Abstract

Get in touch with us

Partner with us

Modelling the impact of respiratory syncytial virus (RSV) vaccine and immunoprophylaxis strategies in New Zealand

Abstract

Sign up for our newsletter to get the latest updates

Sign up for our newsletter